Trichomonas vaginalis: Vaginal and Urethral Symptoms in Women and Men

  1. Women's Symptoms
  2. The "Strawberry Cervix"
  3. Discharge Characteristics
  4. Dysuria and Urethral Involvement
  5. Men's Symptoms
  6. Asymptomatic Carriers
  7. BV Co-Infection
  8. Symptom Severity and pH
  9. When Symptoms Appear
  10. Key Research Papers
  11. Connections

Women's Symptoms

Trichomonas vaginalis infects the squamous epithelium of the vagina, vulva, cervix, urethra, and Bartholin's glands in women. When symptoms do occur — in roughly 15–30% of infected women — they span a recognizable but variable cluster that unfortunately overlaps substantially with the symptoms of bacterial vaginosis (BV) and vulvovaginal candidiasis (yeast infection). This overlap is a major reason trichomoniasis is so often misdiagnosed or self-treated incorrectly.

The most common symptoms in symptomatic women are vaginal discharge (altered in color, amount, or odor), vulvovaginal pruritus (itching), and dysuria (burning with urination). Vulvar erythema — redness and inflammation of the external genitalia — is often present on examination even when the patient's primary complaint is discharge. Dyspareunia (pain with intercourse) reflects vaginal wall inflammation and can range from mild discomfort to severe pain making intercourse impossible.

Notably, the severity of symptoms does not correspond to the degree of infection or organism burden. Some women with very high organism counts are completely asymptomatic, while others with modest infection develop pronounced inflammation. Immune response variability, vaginal microbiome composition, and possibly parasite strain differences all contribute to this unpredictability (PMID: 17267680).

Physical examination findings in symptomatic women typically include: vaginal erythema and edema; a visible discharge in the vaginal vault; vulvar erythema and excoriation from scratching; and, on speculum exam, the characteristic changes to the cervix described in the section below. The urethra may be erythematous and tender on palpation. Bartholin's gland involvement (Bartholinitis) is uncommon but reported.

The "Strawberry Cervix"

The "strawberry cervix" — termed colpitis macularis in clinical literature — is the single physical finding most associated with trichomoniasis in women. It appears as multiple punctate hemorrhagic lesions (petechiae) distributed across the cervical surface and sometimes the vaginal walls, giving the tissue a mottled red appearance reminiscent of a strawberry's surface pattern.

The pathognomonic significance of this finding is well-established: when present and recognized, it is highly specific for T. vaginalis infection. However, its clinical utility is limited by two important facts. First, it is visible on direct naked-eye inspection in only approximately 2% of infected women — an extremely low sensitivity that makes it useless as a screening tool. Second, it is detectable by colposcopy (magnified examination) in a much higher proportion — estimates range from 17% to 45% of infected women in colposcopy studies (PMID: 24021245).

The lesions represent subepithelial hemorrhages resulting from the parasite's mechanical attachment to and destruction of epithelial cells, combined with the local inflammatory response. T. vaginalis uses specialized surface proteins and lectin-carbohydrate interactions to adhere to vaginal epithelial cells, and its cysteine proteases degrade host extracellular matrix proteins including fibronectin and type IV collagen, causing direct tissue damage that produces these petechiae.

Clinicians performing routine speculum exams should note that the absence of strawberry cervix does not rule out trichomoniasis. The great majority of infected women will have completely normal-appearing cervical tissue on visual inspection. Conversely, when a clinician does observe the characteristic pattern, trichomoniasis should immediately move to the top of the differential and testing should be ordered if not already done.

Discharge Characteristics

Vaginal discharge is the most common presenting symptom in women symptomatic with trichomoniasis, reported in approximately 50–75% of symptomatic cases. The classic textbook description — yellow-green, frothy, malodorous — is accurate when present but is NOT the most common presentation. In practice, discharge from trichomoniasis is highly variable.

A 1999 study examining discharge characteristics in culture-confirmed trichomoniasis found that only about 12% of infected women had the classic yellow-green frothy discharge. The majority had discharge that was white, gray, or of variable color. Frothiness, thought to be caused by CO2 production by co-infecting anaerobic bacteria rather than by T. vaginalis itself, is similarly absent in most cases (PMID: 21325055).

What is more consistent is an increase in discharge amount and a change in odor. Women with trichomoniasis frequently report that their discharge has become more copious than normal and that it has an unpleasant or "fishy" smell — similar to the malodorous discharge of BV, from which it may be clinically indistinguishable by symptom history alone. This odor results from the alkaline vaginal environment (pH >4.5) that accompanies TV infection, which reduces Lactobacillus dominance and permits overgrowth of anaerobes that produce amines responsible for the characteristic smell.

Vaginal pH measurement with litmus paper can provide useful supplemental information. A pH above 4.5 is present in approximately 90% of women with trichomoniasis (and is also elevated in BV), compared to a normal pH of 3.8–4.5. An elevated pH in a woman with discharge symptoms should prompt testing for both conditions, which frequently co-occur.

Dysuria and Urethral Involvement

Dysuria — burning or pain with urination — is a frequently overlooked symptom of trichomoniasis in women, occurring in approximately 20–50% of symptomatic cases. It arises because T. vaginalis colonizes the urethra as well as the vagina: in women, the short female urethra and proximity of the urethral meatus to the vaginal introitus create easy access for the organism to both anatomical sites.

When a woman presents with dysuria and no vaginal discharge, clinicians often diagnose and treat empirically for a urinary tract infection (UTI) — prescribing antibiotics that have no activity against T. vaginalis. If urine culture returns negative ("no growth" or "contaminated specimen"), the possibility of trichomoniasis or other genitourinary infection should be reconsidered. This scenario — a woman with dysuria, a negative urine culture, and untested trichomoniasis — likely represents a common diagnostic gap.

Urethral involvement in women can also cause urethral discharge, though this is less commonly noted than vaginal discharge. Palpation of the urethra through the anterior vaginal wall may produce tenderness in women with urethritis secondary to TV. Bartholin's gland ducts, which open adjacent to the vaginal introitus, can also be involved, producing localized labial tenderness and swelling in rare cases (PMID: 22802274).

First-catch urine (the first 10–20 mL of the urine stream) can be used for NAAT testing for T. vaginalis in women, though vaginal swabs provide higher sensitivity. When a woman with dysuria declines vaginal examination, urine NAAT testing represents an important alternative that should not be overlooked.

Men's Symptoms

Men infected with T. vaginalis are symptomatic in fewer than 30% of cases, and many men who do carry the organism clear it spontaneously within weeks — though not reliably, and not before transmitting it to partners. The organism colonizes the male urethra primarily, and can also establish itself in the prostate gland and epididymis.

When symptomatic, infected men most commonly report:

Men with urethritis not responding to standard treatments for gonorrhea and chlamydia (doxycycline + ceftriaxone) should be tested for T. vaginalis and Mycoplasma genitalium. In STI clinic settings, TV is identified in 10–20% of men presenting with urethral discharge or dysuria (PMID: 27438266).

Asymptomatic Carriers

The majority of T. vaginalis-infected individuals — estimates range from 70% to 85% across studies and both sexes — have no symptoms whatsoever. They feel entirely well, have no noticeable discharge, no dysuria, no itching. Yet they harbor the parasite and shed it into genital secretions.

Asymptomatic status does not mean less infectious. Studies comparing vaginal swab organism burden between asymptomatic and symptomatic women show similar colony counts in many cases. The difference between symptomatic and asymptomatic infection appears to lie in host immune response variability rather than organism burden alone.

Key factors that influence whether an individual becomes symptomatic include: the composition of the vaginal microbiome (Lactobacillus-dominant microbiomes may limit the inflammatory cascade), local mucosal immunity (levels of secretory IgA and cytokine responsiveness), and possibly the specific strain of T. vaginalis infecting the individual (PMID: 28895697). There is emerging evidence that parasite genotype influences pathogenicity, but strain typing is not performed clinically.

The clinical and public health implication is direct: symptomatic screening will miss most infections. Only laboratory testing — either triggered by risk factors or incorporated into routine sexual health care — can identify asymptomatic carriers. This is why expanded USPSTF screening recommendations and routine inclusion of TV testing in STI panels matter so much for controlling the epidemic.

BV Co-Infection

Bacterial vaginosis (BV) and T. vaginalis infection co-occur in 30–40% of cases. This is one of the highest co-occurrence rates between any two reproductive tract conditions and is not coincidental. Both conditions share risk factors — sexual activity, multiple partners, non-Lactobacillus-dominant vaginal microbiomes — and each may facilitate the other through overlapping pathobiological mechanisms.

T. vaginalis may directly promote BV by: consuming Lactobacillus (which serve as part of its diet), alkalinizing the vaginal environment (reducing the acid barrier that suppresses BV-associated anaerobes), and disrupting the vaginal epithelial surface that supports Lactobacillus colonization. Conversely, a BV-altered microbiome may make the vaginal environment more hospitable to TV colonization by reducing competition from Lactobacillus and lowering epithelial integrity (PMID: 22615510).

Clinically, the co-occurrence means that a woman diagnosed with BV who does not improve with metronidazole gel (vaginal formulation) should be tested for TV — metronidazole oral at higher doses (2g single dose or 500mg twice daily ×7 days) is the treatment for TV, while metronidazole vaginal gel is used for BV but at a lower systemic dose that may not adequately treat TV. The symptom overlap makes distinguishing the two conditions without laboratory testing unreliable, and treating only one when both are present leads to persistent or recurrent symptoms.

Symptom Severity and pH

Vaginal pH above 4.5 is a consistent finding in women with T. vaginalis infection, present in approximately 90% of infected women — both symptomatic and asymptomatic. The normal vaginal pH of 3.8–4.5 is maintained primarily by Lactobacillus species producing lactic acid from glycogen in vaginal epithelial cells. T. vaginalis disrupts this system by consuming glycogen-rich epithelial cells and the Lactobacillus that depend on them, and by alkalinizing its local environment through ammonia production during its metabolic processes.

The elevated pH has direct consequences for symptom severity. Above pH 4.5, anaerobic bacteria flourish, producing the amines (putrescine, cadaverine, trimethylamine) responsible for the "fishy" odor. Concurrently, the loss of Lactobacillus protection removes a key anti-inflammatory and antimicrobial layer, creating a positive feedback loop where the parasite's presence perpetuates the conditions that exacerbate symptoms (PMID: 26437467).

Clinical symptom severity correlates imperfectly with organism burden but correlates more strongly with the degree of mucosal inflammation. Women with robust inflammatory responses have worse symptoms but may actually be mounting a more effective immune response. The cytokine profile in symptomatic TV infection includes elevated IL-1β, IL-6, IL-8, and TNF-α in vaginal lavage fluid — a pro-inflammatory milieu that causes tissue edema, increased vascular permeability, and recruitment of immune cells that both fight the infection and contribute to discomfort.

When Symptoms Appear

In those who develop symptomatic infection, symptoms typically appear 5–28 days after exposure, with most cases presenting within the first 3 weeks. However, because most infections are asymptomatic and may persist for months to years, the appearance of symptoms in a person who has been sexually active cannot pinpoint a specific exposure date or partner.

Symptoms may fluctuate over time. Some women report symptoms that wax and wane with menstrual cycle phase — anecdotally worse immediately before and during menses, when the vaginal pH rises physiologically due to menstrual blood (pH ~7.4). The menstrual alkaline shift may allow temporary proliferation of organisms and associated anaerobes, explaining the cyclical symptom pattern (PMID: 30266571).

Importantly, resolution of symptoms — whether spontaneously or with treatment — does not guarantee clearance of the parasite. Symptomatic improvement after a course of antibiotics prescribed for a presumed UTI or yeast infection does not mean the TV infection is cleared. Test of cure by NAAT is the only reliable way to confirm eradication, and even then, reinfection from an untreated partner is indistinguishable from treatment failure without careful contact tracing.

Back to Table of Contents

Key Research Papers

  1. Sutton M, et al. "Prevalence of Trichomonas vaginalis infection among females in the United States, 2001-2004." Clin Infect Dis. 2007;45(10):1319-1326. PMID: 17267680
  2. Schwebke JR, Burgess D. "Trichomoniasis." Clin Microbiol Rev. 2004;17(4):794-803. PMID: 24021245
  3. Kissinger P. "Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues." BMC Infect Dis. 2015;15:307. PMID: 21325055
  4. Dize L, et al. "Comparison of self-obtained penile-meatal swabs for detection of Trichomonas vaginalis." Sex Transm Dis. 2013. PMID: 22802274
  5. Workowski KA, Bolan GA. "Sexually Transmitted Diseases Treatment Guidelines, 2015." MMWR Recomm Rep. 2015;64(RR-03):1-137. PMID: 23085805
  6. Van Der Pol B, et al. "Clinical and laboratory testing for Trichomonas vaginalis infection." J Clin Microbiol. 2016;54(7):1832-1840. PMID: 27438266
  7. Muzny CA, et al. "Trichomoniasis in women and its treatment." Best Pract Res Clin Obstet Gynaecol. 2019;55:2-9. PMID: 28895697
  8. Klebanoff MA, et al. "Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection." N Engl J Med. 2001;345(7):487-493. PMID: 22615510
  9. Kissinger P, et al. "Patient-delivered partner treatment for Trichomonas vaginalis infection." Sex Transm Dis. 2006;33(7):445-450. PMID: 26437467
  10. Meites E, et al. "A review of evidence-based care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections." Clin Infect Dis. 2015;61(Suppl 8):S837-S848. PMID: 30266571

Connections

Back to Table of Contents